What Hemafer Treats: Main Uses and Benefits

Hemafer is an oral iron preparation generally used for managing conditions presenting with systemic imbalance due to iron depletion. This preparation is used within the therapeutic area of iron deficiency management.

---

Therapeutic Scope and Benefits

The primary role of Hemafer is in managing established iron deficiency anemia (IDA) and latent iron deficiency, and is used for managing low iron stores. The medication is commonly used to address pronounced symptoms that interfere with daily functioning and accompany iron depletion, such as chronic fatigue, physical weakness, and reduced endurance.

This preparation helps address symptoms related to systemic imbalance, which contributes to easing the overall symptom load and may help improve day-to-day physical comfort. Clinical scenarios where Hemafer is applied include supporting high-demand patient groups like pregnant women and growing children, as well as individuals with sensitive digestion who experience noticeable physiological strain.

Quick Fact: Support for Chronic Fatigue

Regulatory References

1. Health Products Regulatory Authority (HPRA) documentation

Official Eligibility and Non-Eligibility for Hemafer

This section outlines the regulatory criteria for who can and who must not use Hemafer (Iron Hydroxide Polymaltose Complex), based exclusively on government regulatory documents.

Eligibility Status	Patient Populations	Conditions/Restrictions
Contraindicated (Must NOT use)	Patients with Hypersensitivity to the components.	Conditions leading to Iron Overload (e.g., Haemochromatosis, Haemosiderosis).
	Patients with Anemia NOT due to Iron Deficiency.	Conditions like chronic haemolytic anemias, sideroblastic anemias, or anemias of chronic disease.
Conditional/Caution	Patients with known Liver Disease.	Hepatic Cirrhosis is considered a relative contraindication due to the risk of iron deposition.
	Children under 6 years (Use restricted/non-established).	Oral preparations require caution in children aged 6 and older.
Approved (May use)	Pregnant women and Lactating (breastfeeding) women.	Indicated for therapeutic or prophylactic treatment in these life stages.

Regulatory documentation strictly forbids Hemafer's use in any non-sideropenic anemia unless a co-existing iron deficiency is clearly proven. The medicine is explicitly indicated for use throughout pregnancy and lactation. Use in children is generally treated with caution, particularly for those under 6 years, with specific instruction required for administration to older children.

Interactions with other medicines and products

The interaction profile for Hemafer is characterized by specific restrictions and a documented absence of interaction with common chelating agents, stemming from its non-ionic Iron (III) Hydroxide Polymaltose Complex structure. This structure is officially cited as the reason that ionic interaction is unlikely to occur.

• Restricted Combinations and Timing Rules: Co-administration with parenteral iron preparations is not indicated because it results in a documented reduction in the absorption of the oral preparation. For functional reasons, a strict separation of at least 2 hours must be left between the administration of Hemafer and calcium-containing formulations.
• Mitigated Ionic Interactions: Regulatory data confirm that the complex-bound iron is unlikely to cause ionic interaction with common substances. Co-administration of tetracyclines or antacids (such as aluminium hydroxide) has been officially documented as not significantly reducing the absorption of either Hemafer or the co-administered drug.
• Secondary Component Interactions: For Hemafer products co-formulated with Folic Acid, interactions apply to the secondary component. The Folic Acid component may increase the metabolism of phenytoin, potentially leading to lower serum concentrations. Additionally, substances including alcohol (ethanol) and barbiturics are documented to decrease the plasma concentration of Folic Acid.
• Diagnostic Procedural Notes: The use of this iron preparation does not impair the selective Haemoccult Test for the detection of occult blood, meaning iron therapy interruption is not required for this test.

Hemafer is a complex of Iron(III) Hydroxide Polymaltose Complex (IPC), a non-ionic iron compound. Upon oral administration, the compound enters the gastrointestinal tract, where it releases iron(III) ions. The high stability of the complex results in a controlled, non-ionic release of iron.

The intact IPC molecules or the released ferric ions are primarily absorbed by the duodenal enterocytes via active transport mechanisms, and subsequently by the cells of the reticuloendothelial system (RES), particularly macrophages in the liver, spleen, and bone marrow. Within the RES macrophages, the iron is disassociated from the carbohydrate shell. This iron is either directed to intracellular storage proteins, primarily ferritin and hemosiderin, or is subsequently released into the systemic circulation.

Once in the plasma, the ferric iron binds to the transport protein transferrin, forming the ferric-transferrin complex. This complex travels to erythroid precursor cells in the bone marrow, where it interacts with the transferrin receptor to be internalized. Within the erythroblast, the iron is incorporated into the protoporphyrin ring via the enzyme ferrochelatase to synthesize the heme molecule. Heme is then integrated into the globin chains to form hemoglobin. This process supports the final maturation of erythrocytes, increasing the concentration of hemoglobin and the mass of circulating red blood cells, thereby modulating systemic oxygen-carrying capacity.

How to Use Hemafer: Official Administration Guidelines

This section outlines the usage instructions for Hemafer (Ferric Hydroxide Polymaltose Complex). These guidelines define the correct routes, dosages, and administration conditions.

Administration Scope

Scope Component	Instruction
Route of Administration	Primarily Oral (drops, syrup, chewable/effervescent tablets). Parenteral (IV/IM injection) is an approved route when the oral route is not feasible.
Timing in Relation to Meals	Oral forms may be taken with or without food (before, during, or after meals).
Frequency Pattern	Typically once daily (the total daily dose may be taken at one time or divided).

---

Official Dosing and Duration

Official dosages are based on elemental iron (III) content and depend on the patient's age and the severity of the iron deficiency.

• Adults and Adolescents (>12 years): Standard daily dose is 100 mg elemental iron. For severe deficiency, the dose is often initiated at 200 mg daily for the first two weeks, then reduced.
• Children (1–12 years): The daily dose is generally 50 mg to 100 mg elemental iron.
• Infants: Doses range from 25 mg to 50 mg elemental iron daily, with specific rules for premature infants (3.33 mg per kg body weight daily).

Duration of Use: Treatment must continue for at least one month after blood values (e.g., hemoglobin) have normalized. This extended course is intended to ensure that the body’s iron stores are fully replenished.

---

Preparation Requirements

• Oral Drops and Syrup: May be mixed with fruit or vegetable juices, or added to a bottle-feed.
• Effervescent Tablets: Must be dissolved completely in a glass of water before consumption.

Research Evidence / Overview of Studies for Hemafer

This section provides a factual overview of the clinical research conducted on the Iron (III) Hydroxide Polymaltose Complex (Hemafer). It describes the structure of the evidence base, including what outcomes were measured and where research gaps may exist.

---

Evidence for use in Iron Deficiency Anemia (IDA)

Research examined the complex in people with established Iron Deficiency Anemia (IDA), a condition characterized by low iron levels. The core of this research involves Randomized Controlled Trials (RCTs) and comprehensive reviews. The trials included a range of populations, such as non-pregnant adults, pregnant individuals, and children with IDA.

Researchers monitored outcomes reflecting systemic or functional imbalance, focusing mainly on changes in certain blood markers. Specifically, studies tracked the levels of Hemoglobin (Hb) and Serum Ferritin. Findings describe patterns observed in the studies over defined time intervals, typically focusing on measurements taken during the initial study period, usually between two and three months.

---

Evidence for use in Latent Iron Deficiency

Research explored the complex in people who have low iron stores but have not yet developed full anemia, a scenario often referred to as latent iron deficiency. The main purpose of these studies was to monitor the changes in Serum Ferritin concentration.

Research also examined patient-reported outcomes describing perceived functional limitation, such as generalized fatigue and physical endurance metrics. The connection between the measured change in the biomarker and significant, long-term improvement in symptoms like persistent fatigue is not fully established. Research provides limited insight into whether the observed change in the biomarker leads to durable, long-term improvement in these nonspecific symptoms.

---

Research Gaps and Areas of Uncertainty

A primary research gap is the limited information for long-term outcomes, particularly concerning the durability of iron store repletion after a period of treatment. In certain groups, such as children, findings were mixed across different studies, meaning that the overall evidence landscape includes inconsistent reports. Follow-up durations were limited in many primary studies, and data for certain groups remain insufficient to draw definitive conclusions. Study results reflect the specific conditions under which they were conducted and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Effectiveness of iron polymaltose complex in treatment and prevention of iron deficiency anemia in children: a systematic review and meta-analysis

How to Store and Dispose of Hemafer?

Official regulatory documents define strict environmental conditions and handling procedures for Hemafer (Iron (III) Hydroxide Polymaltose Complex) to maintain its stability and ensure safety.

---

Official Storage and Handling Requirements

• Temperature: Store the medicine at a temperature not exceeding 30 C in its original packaging.
• Environment: The product must be stored in a dry place and should not be frozen.
• Child Safety: Due to the risk of accidental poisoning, Hemafer must be kept out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Hemafer should be disposed of in accordance with local regulatory requirements. It must not be thrown away via wastewater or household waste to comply with environmental pharmaceutical guidelines.